STING agonist-45

Overview

STING agonist-45 is a selective STING agonist ( EC 50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS - STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6 ). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 + T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING -related diseases.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > STING | Products > Signaling Pathways > Cyclic GMP-AMP Synthase | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-177338
• CAS No.: 2361424-97-5
• Molecular Formula: C21H26N6O4
• Molecular Weight: 426.47
• Purity: 99.10%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (11.72 mM); Clear solution
• Availability: In-stock

Source

Original product source